The value of rapid functional assays of germline p53 status in LFS and LFL families by Camplejohn, R S et al.
Rare cancer-prone families were first recognized in the late 1960s
with a very particular clinical picture involving early onset
sarcomas, breast carcinoma, brain tumours, leukaemias and
adrenal carcinoma (Li and Fraumeni 1969); these families are said
to exhibit Li–Fraumeni syndrome (LFS). More recently, families
have been recognized with similar spectra of malignancies, which
do not fully meet the precise criteria of classical LFS (Birch et al,
1994; Eeles, 1995). Such families have been called Li–Fraumeni-
like (LFL). In 1990, Malkin et al demonstrated a relationship
between germline p53 mutations and LFS. p53 is a tumour
suppressor gene and mutation and deletion of the gene are the
most common genetic defects seen in sporadic clinical cancer.
Recent reports indicate that up to 75% of families with classical
LFS have germline mutations in the p53 gene as do 10–22% of
LFL families (Eeles, 1995; Varley et al, 1997). The identification
of these mutations is important clinically because carriers are at
markedly increased risk of developing cancer (cumulative lifetime
risk in women 90%) and may be at greater risk of radiation-
induced carcinogenesis (Eeles, 1995).
Point mutations, which disrupt p53 function, were originally
thought to be largely restricted to the core DNA binding region of
p53. However, this central area of p53 has been more extensively
investigated for mutations than either the N- or C-termini, there-
fore the frequency of mutations outside the core domain may be
higher than is thought (Casey et al, 1996). Thus, if sequencing is to
be used to detect all coding germline p53 mutations, then all exons
and splice junctions should be investigated (Varley et al, 1997).
The families with p53-related germline defects are rare and they
often first come to light due to a high incidence of cancer. A rapid
screening assay would be valuable to determine, from the much
larger number of cancer-prone families, the minority due to a p53-
related defect. We have tested two potential assays of p53 function
on a number of LFS/LFL family members as part of a larger study.
The first of these assays was developed in our laboratory and
depends upon the measurement of the apoptotic response of
peripheral blood lymphocytes (PBL) to radiation-induced DNA
damage (Camplejohn et al, 1995). In individuals with functional
p53 most PBL die within 48 h of a dose of 4 Gy radiation, whilst
in individuals with an inherited defect leading to loss of p53 func-
tion PBL are resistant to the lethal effects of radiation. We believe
that this assay will detect any inherited p53 defect which results in
loss of p53 function. The second test, the FASAY, is a yeast-based
assay which tests the ability of p53 protein to transcriptionally
transactivate a target gene by binding to the RGC consensus
sequence (Flaman et al, 1995; Lomax et al, 1997). Functional p53
leads to the growth of white yeast colonies, whilst mutant p53
results in red colonies. This assay is also rapid, inexpensive and
links any detected defect directly to exons 4–10 of the p53 gene.
MATERIALS AND METHODS
Subjects
A minimum of 20 ml of blood was collected from 20 affected and
unaffected members of LFS/LFL families and from 50 normal
individuals with no history of excessive cancer occurrence in their
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were received between the beginning of 1994 and the middle of
1997 are included in this study provided that results for all three
assay methods are available.
Apoptotic assay
PBL were separated from fresh whole blood samples and cultured
in standard medium (RPMI, 10% fetal calf serum, glutamine and
antibiotics) for three days. At 72 h of culture, half of the cells were
exposed to 4 Gy of gamma radiation. Both irradiated and control
cells were returned to the incubator for a further 24 h at which
point the cells were fixed in 70% ethanol at 4°C. For analysis, the
samples were acid-denatured for 12 min in 0.1 M hydrochloric
acid at 37°C and then stained with propidium iodide. The amount
of apoptosis was assessed by the size of the sub-G1 peak on DNA
profiles. In all but a few cases where there were insufficient cells,
flow cytometry was performed in triplicate with good repro-
ducibility. This flow cytometric method has been validated by
comparison with other techniques, including electron microscopic
counting and cell sorting of apoptotic cells (Camplejohn et al,
1995) to confirm that the sub-G1 peak did consist of apoptotic
cells.
FASAY
mRNA extracted from phytohaemagglutinin (PHA)-stimulated
PBL was subjected to the FASAY (Flaman et al, 1995; Lomax et
al, 1997). In this assay, purified mRNA was subjected to reverse
transcription polymerase chain reaction (RT-PCR). The unpurified
p53 RT-PCR product was then co-transfected into yeast with a
linearized expression vector carrying the 5¢ and 3¢ ends of the p53
open reading frame. This results in the constitutive expression of
the human p53 protein present. Yeast that have repaired the
plasmid were selected by their ability to grow in the absence of
leucine and with a limiting concentration of adenine; if the p53 is
wild-type the ADE2 gene is activated, producing adenine and
white colonies are formed. Mutant p53 does not activate the ADE2
gene and the resultant colonies are red due to the accumulation of
a red adenine precursor. This assay recognizes mutations from
exon 4 to exon 10 of the p53 gene as this is the extent of the PCR
product that recombines with the gapped vector. Many control and
repeat experiments were performed to demonstrate the repro-
ducibility of the FASAY, some of these are described in Lomax et
al (1997).
Sequencing
DNA was isolated from PBL by the sucrose lysis method. DNA
fragments were PCR-amplified using the primer sequence below:
Exon 1 – Forward 5¢-GAGAATCCTGACTCTGCACC
Reverse 5¢-AGCCGAGCCCGTGACTCA
Exons 2/3 – Forward 5¢-ATGCTGGATCCCCACTTTTC
Reverse 5¢-AAGAGCAGTCAGAGGACCAG
Exon 4 – Forward 5¢-GACCTGGTCCTCTGACTGCT
Reverse 5¢-GCATTGAAGTCTCATGGAAG
Exon 5 – Forward 5¢-ACTTGTGCCCTGACTTTCAACT
Reverse 5¢-CAATCAGTGAGGAATCAGAGGC
Exon 6 – Forward 5¢-TCAGATAGCGATGGTGAGCAG
Reverse 5¢-GCCACTGACAACCACCCTTA
Exon 7 – Forward 5¢-AGGCGCACTGGCCTCATCTT
Reverse 5¢-GAAATCGGTAAGAGGTGGGC
Exon 8 – Forward 5¢-GGAGTAGATGGAGCCTGGTTT
Reverse 5¢-GGTGATAAAAGTGAATCTGAGGC
Exon 9 – Forward 5¢-GGAGACCAAGGGTGCAGGTTAT
Reverse 5¢-GTTAGTTAGCTACAACCAGGAGCC
Exon 10 – Forward 5¢-CAATTGTAACTTGAACCATC
Reverse 5¢-ATGAGAATGGAATCCTATGG
Exon 11 – Forward 5¢-CTCACTCATGTGATGTCATC
Reverse 5¢-CAAAATGGCAGGGGAGG.
The annealing temperature was 56°C for exons 2–3, 4, 10 and
11 and 60°C for exons 1 and 5–9. To remove the excess primers
and dNTPs before sequencing, the PCR products were purified 
by ammonium acetate and isopropanol precipitation. Cycle-
sequencing of both strands was performed using either of the 
two primers used in PCR with dye-terminator chemistry and
AmplitaqFS (Perkin-Elmer Applied Biosystems). To remove
excess dye before loading samples on to the sequencer the samples
were purified by sodium acetate and ethanol precipitation. The
products were analysed on an ABI 310 sequencer.
RESULTS
In this report the results of the apoptotic assay and the FASAY are
compared with each other and with the results of sequencing. Data
from 20 affected and unaffected individuals who are members of
LFS/LFL families are included (Table 1). These data are compared
to results from 50 normal individuals with no known inherited
susceptibility to cancer. This paper includes data on LFS/LFL
family members collected up to the middle of 1997 as part of an
on-going larger study in which sporadic cancer patients and
members of other types of cancer-prone family (e.g. BRCA1 and
BRCA2) were also investigated. From this larger database we
have defined a normal range of values for the apoptotic assay and
a range denoting the likely presence of a heterozygous germline
p53 mutation. A normal apoptotic response is thus defined as
anything greater than 27%, whilst any value below 23% is consis-
tent with the presence of a mutation. This leaves a borderline
region of 23–27% into which occasional results fall. Such results
are considered as suspicious and worthy of further investigation,
initially with the FASAY.
When comparing the various assays, the results show excellent
agreement between the two functional assays and between them
and sequencing. Both the FASAY and the apoptotic assay success-
fully detected all known carriers of germline p53 defects. In the
apoptotic assay these carriers had responses significantly lower
than those seen in normal individuals and non-affected members
of LFS/LFL families (see Figure 1). Further, in the FASAY all
carriers of germline p53 mutations yielded between 44 and 60%
red colonies, well above the maximum background level of 10%.
In addition, no individuals from the LFS/LFL families who had
homozygous wild-type p53 were classified as abnormal by either
functional assay, though one such individual did yield a borderline
apoptotic assay result.
DISCUSSION
In this study, both of the functional assays detected all known
carriers of germline p53 mutations. Although it requires to be
established with a larger series of mutation carriers, we would
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Table 1 Apoptotic assay results denote a mutation (Mut) if the increase in apoptotic cells after 4 Gy radiation is < 23%,
borderline (B) [23–27%] and wild-type (WT) [> 27%]
Case Family Cancer Apoptotic FASAY Sequencing of exons
status diagnosed in assay 1–11
individual
4001 LFL Yes Mut Mut Mut codon 151
4002 LFS Yes Mut Mut Mut codon 248 (subject
II-2 family 266, Varley
et al 1997)
4005 LFL Yes Mut Mut Mut codon 337
4006 LFL Yes Mut Mut Mut codon 245 (subject
F, Camplejohn et al
1995)
5020 LFL Yes Mut Mut Mut codon 273
6034 LFS Yes Mut Mut Mut codon 213
5004 LFL No WT WT WT
5006 LFL No WT WT WT
5010 LFL No WT WT WT
6023 LFS No WT WT WT
6024 LFS No WT WT WT
6033 LFL No WT WT WT
6072 LFL No WT WT WT
6107 LFL No WT WT WT
6135 LFL No WT WT WT
6137 LFL No B WT WT
6141 LFL No WT WT WT
6146 LFL No WT WT WT
7094 LFL No WT WT WT
7099 LFS No WT WT WT
These figures are based on a study of around 300 samples. Results on 50 normal volunteers yielded a mean apoptotic
response of 44% (1 s.d. 9%). The FASAY was performed as described by Flaman et al (1995) and Lomax et al (1997);
10% or less red colonies denotes a homozygous wild-type result, > 10% red colonies denotes the presence of a mutation.
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Figure 1 The figure shows the distribution of values for the apoptotic response in groups of LFS/LFL individuals with and without p53 mutations and normal
volunteers. The mutation group differs significantly from the LFS/LFL group lacking a mutation (P = 3 ´ 10–5) and the normal group (P = 3 ´ 10–7). The
unaffected and control groups do not differ significantly (P = 0.4). Statistical comparison was done using Fisher’s exact test. Only one sample from the
unaffected and control groups has a lower apoptotic response than any of the affected individuals. Unfortunately, this individual was no longer available for
further studyexpect, in principle, that all germline defects which lead to loss of
p53 function would be detected by the apoptotic assay. However,
the FASAY will only detect mutations between exons 4 and 10 and
will miss mutations which lead to loss of expression of one allele.
In addition, we have found that a splice donor mutation in exon 4,
which leads to the production of three species of aberrant mRNA
was not detected by the FASAY (Varley et al, 1998). We also have
evidence from other studies on sporadic breast tumours that the
FASAY may fail to detect at least some stop mutations in the p53
gene (RS Camplejohn, unpublished data). However, in the current
study as well as detecting all carriers of germline p53 mutations,
no individuals with two wild-type alleles were wrongly identified
as carriers of inherited defects; in the FASAY all such individuals
had < 10% red colonies. In the apoptotic assay non-affected indi-
viduals all gave results above the maximum level seen in gene
carriers, apart from one who gave a borderline result (see Table 1
legend for details). A larger study of sporadic cancer patients and
members of families with other inherited cancer predispositions
suggests that such results are seen occasionally for reasons that are
not yet clear. In addition, a sample from one normal volunteer
gave a low apoptotic response in the range seen with family
members having a p53 mutation. The probability of this individual
having a germline p53 mutation is very low but, unfortunately, no
material was available for further study. However, the apoptotic
assay would only be used as an initial screening technique to
identify cases worthy of further investigation by more detailed
methods such as sequencing. Thus a small number of borderline,
or even false-positive, results would not be a major problem in the
event of the assay being used as a clinical screening test.
Therefore, we consider that both assays show real promise as a
screening process to identify samples which warrant further
molecular sequencing analysis and both have a potential role in
identifying germline p53 mutations in members of cancer-prone
families. As an initial screen the apoptotic assay does have the
great advantages of simplicity and low cost.
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